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ABSTRACT
Background The authors have previously reported
genomic subtypes of chronic fatigue syndrome/myalgic
encephalomyelitis (CFS/ME) based on expression of 88
human genes.
Aim To attempt to reproduce these findings, determine
the specificity of this signature to CFS/ME, and test for
associations between CFS/ME subtype and infection.
Methods Expression levels of 88 human genes were
determined in blood of 62 new patients with idiopathic
CFS/ME (according to Fukuda criteria), six patients with
Q-fever-associated CFS/ME from the Birmingham Q-fever
outbreak (according to Fukuda criteria), 14 patients with
endogenous depression (according to DSM-IV criteria)
and 29 normal blood donors.
Results In patients with CFS/ME, differential expression
was confirmed for all 88 genes. Q-CFS/ME had similar
patterns of gene expression to idiopathic CFS/ME. Gene
expression in patients with endogenous depression was
similar to that in the normal controls, except for
upregulation of five genes (APP, CREBBP, GNAS, PDCD2
and PDCD6). Clustering of combined gene data in
CFS/ME patients for this and the authors’ previous study
(117 CFS/ME patients) revealed genomic subtypes with
distinct differences in SF36 scores, clinical phenotypes,
severity and geographical distribution. Antibody testing
for EpsteineBarr virus, enterovirus, Coxiella burnetii and
parvovirus B19 revealed evidence of subtype-specific
relationships for EpsteineBarr virus and enterovirus, the
two most common infectious triggers of CFS/ME.
Conclusions This study confirms the involvement of
these genes in CFS/ME.
INTRODUCTION
Chronic fatigue syndrome/myalgic encephalo-
myelitis (CFS/ME) is a disease characterised by
severe and debilitating fatigue, sleep abnormalities,
impaired memory and concentration, and musculo-
skeletal pain.1 In the Western world, the population
prevalence is estimated to be of the order of 0.5%.2 3
Research studies have identiﬁed various features
relevant to the pathogenesis of CFS/ME such as
viral infection, immune abnormalities and immune
activation, exposure to toxins, chemicals and
pesticides, stress, hypotension, lymphocyte abnor-
malities and neuroendocrine dysfunction. However,
the precise underlying disease mechanisms and
means by which these abnormalities inter-relate in
patients with CFS/ME remain to be clariﬁed.4 5
Various groups have analysed the gene expression
in peripheral blood of patients with CFS/ME, and,
in all of these studies, genes of immunity and
defence are prominent. Following a pilot microarray
study which identiﬁed 16 abnormally expressed
genes in CFS/ME,6 we reported on a comprehensive
microarray study which reveals abnormal expres-
sion of 88 human genes in patients with CFS/ME.7
Clustering of these data revealed seven genomic
subtypes of CFS/ME with distinct differences in
SF36 scores, clinical phenotypes, severity and
geographical distribution.7 8 However, remaining
questions relate to reproducibility and the speci-
ﬁcity of these gene abnormalities to CFS/ME and
possible associations with infectious agents.
In this study, we set out to determine whether
these ﬁndings were reproducible in fresh subjects,
whether the previously reported dysregulation of
these genes also occurred in drug-free patients with
endogenous depression, and whether there was any
relationship between particular microbial infections
and CFS/ME genomic subtype. The results show
that these ﬁndings are reproducible and that gene
expression in patients with endogenous depression
was markedly different from that in patients with
CFS/ME, and was similar to that in the normal
controls, in terms of these 88 human genes. Also,
clustering of gene data revealed eight genomic
subtypes with distinct clinical differences, and
several of these had interesting associations with
particular microbial infections.
METHODS
Subject enrolment, clinical characterisation and
blood sampling
Patients with CFS/ME (n¼62), who lived in
Birmingham (n¼6), Bristol (n¼3), London (n¼9)
and New York (n¼44), were diagnosed according to
Fukuda diagnostic criteria for CFS/ME1 and enrolled
into the study. All had idiopathic CFS/ME except
the six Birmingham patients, who had CFS/ME
that had been triggered by laboratory-documented
Q fever. Patients with psychiatric disease were
excluded using the Minnesota International
Neuropsychiatric Interview, thus ensuring that
none of our CFS/ME patients had major psychiatric
disease or misused alcohol or other drugs. Clinical
and quantitative PCR (qPCR) data for these new
patients were combined with those for 55 CFS/ME
patients from a previous study,7 8 giving a total of
117 CFS/ME patients, who lived in Birmingham
(n¼6), Bristol (n¼14), Leicester (n¼1), London
(n¼12), New York (n¼55) and Dorset (n¼28).
Patients with endogenous depression (n¼14) were
enrolled from Bristol, UK, and surrounding area. These
patients fulﬁlled Diagnostic and statistical manual of
mental disorders, 4th edition (DSM-IV) criteria, had not
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smokedwithin the previous year, and had not taken antidepressants
in the previous year.
Healthy normal blood donors enrolled from the Dorset
National Blood Service (n¼29) were used as a comparison group.
Restrictions imposed by the Dorset National Blood Service on
those allowed to donate blood are outlined elsewhere.6
For all patient groups, individuals who smoked in the previous
year, who abused alcohol or other drugs, or were currently
taking (or were within 3 months of taking) antibiotics, steroids,
cytotoxic drugs or antidepressants were excluded from the study.
For all enrolled subjects (patients and controls), according to
the recommendations of the International CFS Study Group,9
severity of physical and mental fatigue was assessed using the
Chalder Fatigue Scale,10 level of disability was assessed using the
Medical Outcomes Survey Short Form-36 (SF36), accompanying
symptomswere characterised using the Somatic and Psychological
Health Report, sleep abnormalities were assessed using the Pitts-
burgh Sleep Questionnaire, and assessment of type and severity of
pain was performed using the McGill Pain Questionnaire.
Patients and controls gave informed written consent according
to guidance of the Wandsworth Research Ethics Committee
(approval number 05/Q0803/137). For the New York patients,
approval of the local institutional review boardwas obtained. The
human experimentation guidelines of the US Department of
Health and Human Services were followed in this study.
A 2.5 ml sample of blood was taken from both CFS/ME
patients and normal blood donors (as part of routine blood
donation) into PAXgene tubes (PreAnalytix, Qiagen, UK), and
total RNA extracted using the PAXgene blood RNA kit (PreA-
nalytix), according to the instructions of the manufacturer. RNA
quality and amount were conﬁrmed by micro-spectrophotom-
etry (Nanodrop, Rockland, Delaware, USA). Total RNA samples
used in this study had an absorbance ratio (A260/A280) of 1.9e2.0.
Quantitative PCR
qPCR (Applied Biosystems, Foster City, California, USA) was
used to quantitate the amount of mRNA for 88 CFS/ME-asso-
ciated human genes by the comparative method, using custom
384-well low-density arrays and the ABI PRISM 7900HT
instrument (Applied Biosystems), with glyceraldehyde-3-phos-
phate dehydrogenase as the endogenous control gene. Experi-
ments were performed in triplicate using the protocol described
previously.6 7 Data were displayed using SDS v2.2 software
(ABI), discordant data between replicates were omitted, and
results for each low-density array were calculated and loaded into
ABI SDS v2.2 Enterprise Edition software.
The threshold cycle (Ct) for each test gene in each sample was
compared with that for glyceraldehyde-3-phosphate dehydro-
genase to calculate a ΔCt value. ΔCt values were then normalised
to the calibrator sample to give the ΔΔCt values. Relative quan-
tities (RQ) (2ΔΔCt) of each mRNA of interest were then
calculated. Samples showing a difference between minimum and
maximum RQ values of $100 (indicating poor replicate concor-
dance) were excluded. The t test was used to compare mean RQ
values between groups. p#0.05 was taken to be signiﬁcant.
Clustering of qPCR-generated gene values of CFS/ME patients
Ct values for all 88 CFS/ME-associated genes in 117 CFS/ME
patients were then normalised and clustered using Genesis
software.11 For each of the eight CFS/ME subtypes identiﬁed
using this approach, mean RQ values were calculated for each
gene, and used to generate fold-difference (CFS/ME/normal)
values for each gene in each CFS/ME subtype. Mean fold-differ-
ence values for each gene in each CFS/ME subtype were then
clustered with andwithout normalisation/median centring using
Cluster v2.11 software and visualised using Treeview v1.60
software.12 The clustering algorithm in both of these software
programs has been described previously.12
Detection of anti-microbial antibodies
IgM and IgG antibodies speciﬁc to four microbes that are well
recognised to trigger CFS/ME were detected by ELISA, according
to the manufacturer ’s instructions: Epstein-Barr virus (EBV)
(viral capsid antigen (VCA) IgM and IgG, early antigen IgG and
EpsteineBarr nuclear antigen (EBNA) IgG; Meridien Bioscience
Inc, Cincinnati, Ohio, USA), enterovirus (all serotypes; Virion
Serion, Wurzberg, Germany), parvovirus B19 (viral protein 2 IgM
and IgG; Biotrin, Dublin, Ireland) and Coxiella burnetii (phase I
and II IgG; Virion Serion).
Statistical testing
Testing of the signiﬁcance of associations of gene expression
levels with different patient groups was performed using a two-
tailed t test. Testing of the signiﬁcance of association between
clinical variables and CFS/ME genomic subtype was performed
using c2, analysis of variance (ANOVA) and the ManneWhitney
U tests. Testing of the signiﬁcance of association between
microbial markers in CFS/ME and CFS/ME subtypes was
performed using c2 analysis and ANOVA.
RESULTS
Subjects and clinical characterisation
A total of 117 patients with CFS/ME fulﬁlling Centers for
Disease Control diagnostic criteria were used in this study. For
55, previously published data were used, while the remaining 62
had not previously been tested; for six of these, CFS/ME disease
had been triggered by laboratory-documented C burnetii infec-
tion. In addition, 14 patients with endogenous depression and 29
normal blood donors were studied.
A summary of the clinical details of these subjects is shown in
table 1. In general, all CFS/ME groups had similar proﬁles of
symptoms and mean clinical scores, and Q-CFS/ME was
phenotypically similar to the other CFS/ME cases in which the
triggering factors were unknown. Patients with endogenous
depression had a markedly low prevalence of numbness/tingling
and tender lymphadenopathy, and less bodily pain, as indicated
by the McGill Pain Questionnaire mean score, as compared with
CFS/ME. Normal blood donors had very low prevalence of all
symptoms, little fatigue (Chalder), pain (McGill), associated
symptoms (Somatic and Psychological Health Report), normal
sleep (Pittsburgh Sleep Questionnaire Index) and high SF36 total
scores (table 1), as would be expected.
Quantitative PCR
qPCR was carried out using TaqMan primers/probes speciﬁc for
88 human genes that were previously found to be differentially
expressed in CFS/ME patients.7 This analysis conﬁrmed that
most of these genes differed signiﬁcantly between CFS/ME and
the normal group. Of the 88 genes, 84 were found to be upre-
gulated and four were downregulated (HIF1A, IL7R, PAPOLA,
SHPRH), which is similar to what we reported previously.7 Gene
expression in patients with Q-CFS/ME was also found to be
markedly different from the normal group, and very similar to
that found in patients with CFS/ME. Gene expression in patients
with endogenous depression did not differ markedly from that in
the normal group, except in the case of ﬁve genes (APP, CREBBP,
GNAS, PDCD2, PDCD6), where signiﬁcant upregulation (fold
difference $1.5) was found (table 2).
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Genomic CFS/ME subtypes
Clustering of DCt values for the 88 CFS/ME-associated genes in
the 117 CFS/ME patients identiﬁed eight subtypes (designated
AeH), consisting of 27, 6, 19, 5, 21, 13, 19 and 4 CFS/ME
patients, respectively. There were three patients whose gene
proﬁle did not ﬁt into any of these eight subtype groupings.
Mean fold-difference values for each CFS/ME subtype are shown
in table 3 and ﬁgure 1. Most genes in each subtype were shown to
be upregulated (ﬁgure 1 and table 3).
The relationship between the subtypes of the present study
and those of the previous study which examined only 55 CFS/ME
patients7 8 may be difﬁcult to determine. As these subtypes are
derived by using clustering, which ﬁnds similar groups on the basis
of gene expression values, there is no means to predict the
outcome of the clustering. As there was incomplete preservation
of the previous CFS/ME patient groupings in the present study,
we have designated the subtypes, AeH, to distinguish them from
those of the previous study, which were designated 1e7.7
Analysis of sex ratios for each subtype reveals that subtype D
is made up of females only, subtype H is made up of equal
numbers of males and females, and the remaining subtypes are
made up predominantly of females.
It is particularly interesting that ﬁve of six CFS/ME patients
with Q-CFS/ME clustered in the same subtype (subtype A).
The clinical phenotype was distinct between subtypes.
Subtype D was the most severe, having the lowest scores for
SF36 modules RP, VIT, GH, BP and total score, and the highest
frequency of occurrence of muscle pain and sleep problems
(see ﬁgure 2 for deﬁnitions of abbreviations for SF36 modules).
Subtype B was the least severe, having the highest scores for SF36
modules RP, GH, MH and total score. Subtype B had a higher
median score for the SF36-RP (physical role) than all the others
combined (87.5 vs 0), p¼0.04; ManneWhitney U test). However,
subtype B had the highest frequency of cognitive dysfunction,
muscle weakness and post-exertional malaise. Subtype B showed
a higher frequency of cognitive dysfunction than all non-subtype
B patients combined (p¼0.03) and showed an increased severity
and duration of headache compared with all non-subtype B
patients combined (p¼0.02). Subtype B also had a higher median
score for mental fatigue (Chalder scale) than all non-subtype B
patients combined, although this did not reach signiﬁcance (9.5
vs 7.0; p¼0.06). Subtypes B and C had the best mental health
scores, and subtypes A and F had the worst (ﬁgure 2A,B).
Subtype E had a higher median score for SF36-VIT than all the
others combined (35.0 vs 15.0; p¼0.05; ManneWhitney U test).
Subtype E resulted in the highest frequency of gastrointestinal
problems. Patients of subtype F showed a higher frequency of
increased severity of numbness/tingling compared with all non-
subtype F patients combined (p¼0.03). Patients of subtype H
showed an increased frequency of severity of sore throat
compared with all non-subtype H patients combined (p¼0.01)
(ﬁgure 2A,B).
As regards possible association of subtype with geographical
location, there was evidence to support this, as we found
previously.7 Predominant subtypes in each geographical location
were as follows: Birmingham, subtype A; Bristol, subtype C;
Table 1 Patient information including age, sex, symptoms and questionnaire results summarising fatigue severity, pain, sleep, general function and
associated symptoms for patients with CFS/ME and normal blood donors enrolled in microarray and real-time PCR studies, respectively
Variable
CFS/ME
patients in
previous study7
(n[55)
CFS/ME
patients,
previously
untested
(n[56)
Q-CFS/ME
patients*
(n[6)
All CFS/ME
patients
(n[117)
Patients with
endogenous
depression
(n[14)
Normal blood
donors
(n[29)
Gender (M:F) 19:36 10:46 6:0 35:82 4:10 14:15
Mean age (years) 41.6 40.25 41.5 41.3 41.36 44.6
Mean duration of disease
(years:months)
3.17 2.9 5.7 3.4 0:6 NA
Symptoms/signs
Headache 26 30 1 57 5 1
Sore throat 27 29 0 56 1 1
Poor memory/concentration 30 46 4 80 11 3
Muscle pain 37 42 6 85 5 2
Muscle weakness 36 31 5 72 2 1
Joint pain 41 52 6 99 8 1
Post-exertional malaise 47 54 5 106 9 2
Sleep problem 44 24 0 68 4 3
Gastrointestinal problems 35 36 2 73 6 1
Fainting/dizziness 25 45 5 75 8 1
Numbness/tingling 24 25 2 51 1 0
Tender lymphadenopathy 27 22 2 51 0 0
Mean scores
Physical fatigue (Chalder) 16.13 14.36 10.83 15.15 14.00 7.69
Mental fatigue (Chalder) 8.05 7.34 6.00 7.98 7.42 4.24
McGill Pain Questionnaire 15.28 18.57 18.80 17.58 9.67 2.48
Sphere questionnaire 11.25 11.21 7.33 10.87 12.45 2.07
SF36 questionnaire 46.45 38.65 52.85 45.12 46.19 83.61
Pittsburgh Sleep
Quality Index
10.22 10.00 8.17 10.01 12.25 4.28
*These six Q-CFS/ME patients were all part of the 1989 Birmingham Q-CFS/ME outbreak cohort.
CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis; NA, not applicable; Sphere, Somatic and Psychological Health Report.
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Table 2 CFS/ME-associated genes and transcription factors in patients with CFS/ME, Q-fever-associated CFS/ME and endogenous depression
Gene symbol
GenBank
accession
number Taqman assay IDz
CFS/ME (n[111) Q-CFS/ME (n[6)
Endogenous depression
(n[14)
Fold
difference p Value
Fold
difference p Value
Fold
difference p Value
ABCD4* NM_020323 Hs00245340_m1 2.21 0.01 3.01 0.031 1.42 0.26
ACTR3 NM_005721 Hs00828586_m1 13.53 0.0029 17.77 0.04 1.22 0.72
AKAP10 NM_007202 Hs00183673_m1 5.22 0.01 6.28 0.031 1.16 0.38
ANAPC11* NM_016476 Hs00212858_m1 2.57 0.006 1.47 0.002 1.11 0.37
ANAPC5 NM_016237 Hs00212120_m1 2.04 0.002 1.07 0.045 1.32 0.392
APP NM_201413 Hs00169098_m1 1.42 0.00003 0.23 0.001 1.59 0.021
ARL4C NM_005737 Hs00255039_s1 7.15 0.00001 5.25 0.0023 1.18 0.76
ARPC5 NM_005717 Hs00271722_m1 3.71 0.000008 4.26 0.0047 1.46 0.49
ARSD NM_001669 Hs00534692_m1 1.62 0.001 1.65 0.05 1.07 0.133
ATP6V1C1 NM_001695 Hs00184625_m1 2.66 0.0009 2.03 0.021 1.23 0.75
BCOR NM_017745 Hs00372369_m1 1.90 0.0045 2.37 0.007 1.09 0.28
BMP2K NM_198892 Hs00214079_m1 8.05 0.01 14.27 0.04 1.18 0.125
BRMS1* NM_015399 Hs00363036_m1 3.08 0.0002 2.43 0.037 1.28 0.194
CD2BP2* NM_006110 Hs00272036_m1 4.12 0.000084 5.15 0.001 1.44 0.334
CD47 NM_198793 Hs00179953_m1 3.38 0.0007 2.60 0.002 1.07 0.125
CEP350 NM_014810 Hs00402774_m1 3.85 0.001 6.49 0.01 1.36 0.803
CITED2 NM_006079 Hs00366696_m1 5.28 0.000031 6.21 0.049 1.33 0.172
CMTM6 NM_017801 Hs00215083_m1 3.61 0.014 6.31 0.046 1.21 0.405
CREBBP NM_004380 Hs00231733_m1 7.02 0.02 9.82 0.025 1.61 0.021
CRK NM_016823 Hs00180418_m1 1.98 0.000044 1.29 0.0003 1.40 0.683
CTBP1 NM_001328 Hs00179922_m1 5.13 0.071 4.16 0.02 1.45 0.134
CXCR4 NM_003467 Hs00607978_s1 13.46 0.00009 28.13 0.007 1.05 0.128
EBI2 NM_004951 Hs00270639_s1 5.99 0.002 26.16 0.011 0.88 0.687
EGR1 NM_001955 Hs00152928_m1 1.69 0.03 0.34 0.026 1.33 0.65
EGR3 NM_004421 Hs00231780_m1 2.11 0.017 e e e e
EIF2B4* NM_172195 Hs00248984_m1 2.87 0.0026 1.13 0.048 0.58 0.739
EIF3S10 NM_003750 Hs00186707_m1 2.10 0.0034 1.55 0.067 1.29 0.295
EIF4G1* NM_198241 Hs00191933_m1 2.42 0.0007 0.34 0.035 1.16 0.165
EIF4G3 NM_003760 Hs00186804_m1 2.17 0.00012 3.22 0.0079 1.35 0.83
ETS1 NM_005238 Hs00901425_m1 30.82 0.0008 37.57 0.055 1.09 0.761
FAM126B NM_173822 Hs00545158_m1 3.19 0.01 5.52 0.03 1.26 0.906
FNTA NM_002027 Hs00357739_m1 3.86 0.0007 2.80 0.001 1.24 0.254
GABARAPL1* NM_031412 Hs00744468_s1 5.27 0.00042 1.83 0.008 1.47 0.525
GABPA NM_002031 Hs00745591_s1 15.40 0.0001 1.91 0.027 1.12 0.716
GCN1L1 NM_006836 Hs00412445_m1 1.18 0.00072 0.70 0.0015 1.07 0.443
GLTSCR2 NM_015710 Hs00414236_m1 5.49 0.0016 5.03 0.038 1.17 0.807
GNAS NM_080425 Hs00255603_m1 2.37 0.000045 1.56 0.0021 1.56 0.004
GSN* NM_198252 Hs00609276_m1 2.56 0.00037 2.40 0.01 1.11 0.312
GTF2A2 NM_004492 Hs00362112_m1 1.08 0.002 0.52 0.039 1.13 0.375
HIF1A NM_001530 Hs00153153_m1 0.66 0.019 2.67 0.012 1.28 0.255
IFNAR1 NM_000629 Hs00265057_m1 3.30 0.00025 3.02 0.009 1.32 0.853
IL10RA* NM_001558 Hs00387004_m1 1.34 9.87E-06 e e e e
IL6R NM_000565 Hs00794121_m1 2.49 0.06 e e e e
IL6ST NM_002184 Hs00174360_m1 3.34 0.0011 1.67 0.034 1.36 0.617
IL7R NM_002185 Hs00233682_m1 0.52 0.032 e e e e
JAK1 NM_002227 Hs00233820_m1 12.73 0.0000008 15.51 0.04 1.05 0.623
KHSRP* NM_003685 Hs00269352_m1 1.82 0.00026 0.35 0.0016 1.22 0.55
MAPK9 NM_139070 Hs00177102_m1 1.58 0.045 1.29 0.05 0.95 0.213
METTL3 NM_019852 Hs00219820_m1 1.30 0.0001 0.77 0.01 1.17 0.215
MRPL23* NM_021134 Hs00221699_m1 2.62 0.001 0.80 0.029 1.36 0.79
MRPS6 NM_032476 Hs00606808_m1 2.75 0.025 1.87 0.014 1.34 0.451
MRRF NM_138777 Hs00751845_s1 8.23 0.0004 2.84 0.03 1.22 0.25
MSNy NM_002444 Hs00792607_mH 4.85 0.0016 7.49 0.002 1.35 0.962
MTMR6 NM_004685 Hs00395064_m1 6.60 0.0025 4.12 0.048 1.12 0.15
NFKB1 NM_003998 Hs00231653_m1 5.01 0.00027 5.01 0.001 1.28 0.41
NHLH1 NM_005589 Hs00271582_s1 58.31 7.00E-04 e e e e
NR1D2 NM_005126 Hs00233309_m1 2.06 0.00016 1.56 0.0006 0.73 0.96
NTE* NM_006702 Hs00198648_m1 2.92 0.001 7.34 0.02 1.49 0.579
NUFIP2 NM_020772 Hs00325168_m1 2.37 0.001 2.00 0.046 1.31 0.929
PAPOLA NM_032632 Hs00413685_m1 0.62 0.00021 0.45 0.001 1.37 0.672
Continued
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Leicester, subtype C; London, subtype C, then subtype G; New
York, subtype E, then subtypes G, A, C and F; Dorset, subtypes A,
F, B. Subtype A was prominent in New York, Birmingham and
Dorset; subtype B was prominent in Dorset; subtype C was
prominent in Bristol, London and New York; subtype D was
prominent in Bristol and London; subtype E was prominent in
New York; subtype F was prominent in Dorset and New York;
subtype G was prominent in New York; subtype H was prom-
inent in Dorset (ﬁgure 2C).
Microbial infections
The presence and titre of speciﬁc antibodies (IgM and IgG) to
four treatable microbial infections that are well recognised as
triggers of CFS/ME were also determined in serum samples;
these were EBV, enterovirus, parvovirus B19 and C burnetii. The
seroprevalence (proportion of subjects who were positive for
speciﬁc IgG) of each of these infections was typical of the general
population: EBV (based on VCA IgG), 88%; enterovirus, 49%;
parvovirus B19 (based on viral protein 2 IgG), 74%; C burnetii
(based on phase I or II IgG), 10%. Of the 11 patients who had
C burnetii IgG, ﬁve were patients whose CFS/ME disease had
been triggered by laboratory-documented Q fever.
CFS/ME patients with acute infection with one or more of these
agents (IgM or acute phase IgG) were also detected: EBV (based on
VCA IgM) (n¼3), enterovirus (n¼6), parvovirus B19 (n¼1),
C burnetii (based on phase II IgG) (n¼12). Of the 12 patients who
were positive for C burnetii phase II IgG, ﬁve had Q-CFS/ME. There
were no acute infections detected in the normal group.
Regarding EBV serology, there were also associations between
CFS/ME subtype and both EBV VCA IgM titre (p¼0.0038) and
EBV EBNA IgG titre (p¼0.0011) (ﬁgure 2D). Using the EBV
markers VCA IgM, VCA IgG, early antigen IgG and EBNA IgG,
we determined the EBV serostatus of infection for each subject (ie,
seronegative, primary infection/re-activation, late phase of infec-
tion). Among 111 of these CFS/ME patients, there were 11
seronegative, 61 primary/re-activation and 39 late phase of
infection, as comparedwith the normal group, in which there was
one seronegative, eight primary/re-activation, and 19 late phase of
infection (c2¼9.91, degrees of freedom¼2, p¼0.007) (ﬁgure 2E).
The distribution of CFS/ME patients by EBV serostatus
category (seronegative, primary/re-activation and late phase of
infection) across the eight CFS/ME genomic subtypes is shown
in ﬁgure 2E. In the normal controls, the predominant category of
EBV serostatus was late phase of infection, whereas in the
CFS/ME subtypes, the predominant category of EBV serostatus
was primary/re-activation, which was seen in subtypes A, B, C,
D, F and H. Subtype G had equal numbers of primary/re-acti-
vation and late phase, and subtype E had a predominance of late
phase subjects, but also had ﬁve seronegative subjects. This
distribution was found to be almost statistically signiﬁcant
(c2¼25.9, degrees of freedom¼16, p¼0.055).
EBV-associated genes in each CFS/ME subtype
Within the CFS/ME-associated gene signature of 88 human
genes, there were 12 that have recognised associations with EBV
infection; these associations have been summarised previously.7
Table 2 Continued
Gene symbol
GenBank
accession
number Taqman assay IDz
CFS/ME (n[111) Q-CFS/ME (n[6)
Endogenous depression
(n[14)
Fold
difference p Value
Fold
difference p Value
Fold
difference p Value
PDCD2* NM_002598 Hs00751277_sH 5.38 0.008 e e 1.62 0.029
PDCD6 NM_013232 Hs00737034_m1 2.54 0.0002 2.19 0.01 1.69 0.015
PEX16* NM_004813 Hs00191337_m1 3.98 0.0061 3.32 0.028 0.68 0.776
PGM2 NM_018290 Hs00217619_m1 4.28 0.000001 3.50 0.0014 1.07 0.308
PIK3R1 NM_181523 Hs00236128_m1 4.04 0.005 2.60 0.01 1.14 0.208
PKN1* NM_213560 Hs00177028_m1 4.58 0.0003 3.95 0.01 1.03 0.887
POLR2G* NM_002696 Hs00275738_m1 2.71 0.001 1.00 0.039 0.77 0.916
PPP2R5C NM_002719 Hs00604902_m1 4.65 0.013 8.21 0.045 1.30 0.906
PRKAA1 NM_006251 Hs01562315_m1 4.19 0.0002 2.18 0.001 1.29 0.56
PRKAR1A NM_002734 Hs00267597_m1 3.55 0.0000004 2.31 0.0001 1.23 0.83
PUM2 NM_015317 Hs00209677_m1 2.73 0.00078 2.33 0.002 1.35 0.82
RAP2C NM_021183 Hs00221801_m1 6.74 0.013 4.37 0.043 1.46 0.69
REPIN1 NM_013400 Hs00274221_s1 4.51 0.00001 2.13 0.01 1.26 0.41
RNF141 NM_16422 Hs00212656_m1 6.49 0.00000079 7.44 0.0003 1.19 0.411
SELENBP1 NM_003944 Hs00187625_m1 10.57 0.001 7.00 0.02 1.06 0.104
SFXN1 NM_022754 Hs00224259_m1 1.69 0.041 0.69 0.037 1.00 0.24
SHPRH NM_173082 Hs00542737_m1 0.56 0.02 0.69 0.03 1.00 0.303
SNAP23 NM_003825 Hs00187075_m1 7.00 0.0006 3.17 0.01 1.10 0.132
SORL1 NM_003105 Hs00268342_m1 1.67 4.10E-08 e e e e
SOS1 NM_005633 Hs00362308_m1 1.02 0.001 1.02 0.037 1.27 0.52
TAF11 NM_005643 Hs00194573_m1 1.17 0.001 0.00 0.02 1.40 0.57
TCF3 NM_003200 Hs00413032_m1 2.40 0.03 1.63 0.068 1.29 0.86
TDP1 NM_018319 Hs00217832_m1 3.12 0.001 3.16 0.01 1.12 0.83
TNFRSF1A NM_001065 Hs00533560_m1 12.37 0.004 18.52 0.03 0.86 0.279
UBTF NM_014233 Hs00610729_g1 6.38 0.002 2.40 0.011 1.09 0.297
USP38 NM_032557 Hs00261419_m1 3.35 0.01 4.98 0.078 1.43 0.367
WAPAL NM_015045 Hs00386162_m1 3.94 0.003 3.69 0.026 1.17 0.44
WDR26 NM_025160 Hs00228535_m1 1.36 0.0008 0.71 0.01 1.48 0.95
*Genes found in pilot study.13
yGenes found in study using differential display/PCR.7
zTaqman assays were those pre-designed by Applied Biosystems, Warrington, UK.
CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis.
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Table 3 Fold-difference values for 88 genes in each of eight subtypes (AeH) in 114 subtyped patients with chronic fatigue syndrome/myalgic
encephalomyelitis (CFS/ME). Genes without values for the subtypes are those for which there was missing data for one or more subtypes. Bold type
indicates genes targeted by existing drugs and those CFS/ME subtypes in which fold-difference values of 1.5 were found
Gene
symbol
Genbank
accession
CFS/ME subtype
A B C D E F G H
ABCD4 NM_020323 1.40 0.60 0.81 4.40 10.61 7.02 1.32 0.93
ACTR3 NM_005721 10.17 8.03 4.34 25.73 13.95 6.75 27.57 5.35
AKAP10 NM_007202 3.83 3.25 1.68 8.39 5.59 6.61 4.89 1.64
ANAPC11 NM_016476 2.53 2.66 4.34 3.74 1.59 4.16 2.27
ANAPC5 NM_016237 1.13 1.26 4.49 1.92 0.78 0.00 2.96 2.95
APP NM_201413 0.63 1.73 1.42 0.56 4.64 0.84 0.84 2.58
ARL4C NM_005737 6.62 7.40 2.72 5.85 7.82 8.76 6.68 2.81
ARPC5 NM_005717 2.55 0.81 1.53 5.65 4.87 3.41 4.92 3.01
ARSD NM_001669 0.64 1.17 1.51 4.60 2.62 0.26 0.12 2.19
ATP6V1C1 NM_001695 1.99 3.80 3.38 2.43 2.06 0.72 3.63 4.55
BCOR NM_017745 1.42 2.22 1.78 2.30 6.52 1.13 2.65 2.57
BMP2K NM_198892 8.96 4.83 2.62 16.42 7.76 3.78 11.57 2.06
BRMS1 NM_015399 1.31 4.38 2.44 1.53 4.62 7.06 2.57 3.83
CD2BP2 NM_006110 3.89 1.37 2.21 6.77 4.52 1.33 5.99 3.55
CD47 NM_198793 2.60 6.90 3.37 3.66 4.06 0.95 4.13 2.75
CEP350 NM_014810 3.50 4.47 3.66 5.30 4.50 1.22 5.04 2.04
CITED2 NM_006079 6.43 6.84 1.97 4.95 6.02 4.40 5.50 3.42
CMTM6 NM_017801 3.10 3.70 0.69 10.04 7.81 4.77 1.71 0.73
CREBBP NM_004380 7.11 1.62 1.09 13.34 5.46 2.61 8.99 3.62
CRK NM_016823 1.83 5.57 1.26 2.82 4.89 1.03 2.25 2.02
CTBP1 NM_001328 4.95 4.98 1.05 8.62 15.44 3.43 2.42 2.73
CXCR4 NM_003467 13.47 2.18 2.03 28.10 17.57 1.48 10.29 3.57
EBI2 NM_004951 5.67 1.41 2.31 14.93 5.99 0.76 0.42 4.47
EGR1 NM_001955 0.49 2.85 2.42 0.30 0.27 1.00 1.98 2.96
EGR3 NM_004421 0.95 1.33 0.46 5.36 1.39 0.98
EIF2B4 NM_172195 1.44 0.52 1.33 6.00 3.48 0.15 1.69 2.08
EIF3S10 NM_003750 1.43 4.42 2.10 1.72 1.48 1.25 2.83 6.16
EIF4G1 NM_198241 1.13 3.47 3.52 0.99 1.39 2.30 4.53 14.27
EIF4G3 NM_003760 2.40 0.79 0.77 5.46 27.42 1.09 3.62 1.55
ETS1 NM_005238 35.12 4.63 4.16 52.65 30.36 17.54 24.17 6.91
FAM126B NM_173822 2.04 0.63 0.91 10.18 5.51 2.59 1.31 0.71
FNTA NM_002027 1.39 5.72 2.99 3.88 5.07 2.14 7.88 4.06
GABARAPL1 NM_031412 6.08 6.42 3.37 2.93 8.49 2.58 6.23 5.74
GABPA NM_002031 11.96 8.56 21.93 3.10 5.71 25.83 13.38 55.99
GCN1L1 NM_006836 0.80 1.40 1.91 0.44 5.85 1.13 1.59 2.38
GLTSCR2 NM_015710 3.68 2.46 0.53 4.94 6.98 4.07 10.28 0.80
GNAS NM_080425 1.72 1.13 1.81 3.62 3.18 1.96 3.47 2.20
GSN NM_198252 1.73 1.27 1.69 3.82 2.36 1.64 3.51 5.81
GTF2A2 NM_004492 0.71 0.53 1.21 0.53 2.19 0.48 1.65 0.87
HIF1A NM_001530 2.04 0.87 0.82 5.14 4.22 1.66 4.65 1.35
IFNAR1 NM_000629 1.86 0.17 0.79 3.55 5.53 1.41 7.17 0.91
IL10RA NM_001558 1.12 2.68 0.74 2.31 1.01 1.76
IL6R NM_000565 2.19 2.47 2.78 2.67
IL6ST NM_002184 2.61 1.49 4.81 3.14 3.07 2.67 3.76
IL7R NM_002185 1.43 0.91 1.66 1.46 2.06 1.33
JAK1 NM_002227 9.72 7.84 3.29 28.88 9.80 11.17 18.75 6.19
KHSRP NM_003685 0.42 1.03 0.91 0.61 1.15 0.75 1.07 1.62
MAPK9 NM_139070 1.16 1.62 1.68 1.83 0.00 2.51
METTL3 NM_019852 0.81 1.38 0.64 1.72 2.92 1.08 1.81 0.68
MRPL23 NM_021134 2.34 0.97 1.23 4.15 4.20 1.56 2.56 2.06
MRPS6 NM_032476 2.03 0.92 2.93 3.05 7.75 1.77 1.95 2.00
MRRF NM_138777 10.11 13.30 3.96 2.03 9.28 1.33 9.70 7.34
MSN NM_002444 3.20 1.66 1.81 9.47 7.86 3.13 8.58 2.12
MTMR6 NM_004685 3.71 11.73 2.61 7.73 7.33 2.67 14.97 2.58
NFKB1 NM_003998 3.74 0.91 0.65 8.83 6.51 4.10 7.30 1.55
NHLH1 NM_005589 26.32 37.92 49.09 66.39 51.25 126.29
NR1D2 NM_005126 1.40 2.31 4.57 3.69 1.27 2.50 2.29
NTE NM_006702 1.75 0.31 0.89 3.92 4.37 1.30 3.87 1.43
NUFIP2 NM_020772 1.55 1.90 1.81 2.83 2.10 1.84 3.50 2.31
Continued
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The fold-difference values for each of these 12 genes in eachCFS/ME
subtype/normal were analysed for signiﬁcant associations
using ANOVA.With all 12 genes, there was a trend which did not
reach signiﬁcance (df¼89,p¼0.119). However, when GABPA and
EGR1 were removed from the analysis, the remaining 10 genes
showed a striking association with subtype (ANOVA, df¼73,
p¼0.0001) (ﬁgure 2F).
DISCUSSION
We have previously reported the differential expression of 88
human genes in CFS/ME and evidence of clinically relevant
subtypes.7 8 In the present study, we have conﬁrmed this differ-
ential expression in 62 additional and previously untested CFS/ME
patients. Combining the previous cohort and the new cohort,
we have found evidence of eight genomic CFS/ME subtypes
with marked differences in global functioning, clinical symp-
toms, levels of severity and geographical distribution. The func-
tion of these genes and their networks has been published
previously.7
We have addressed the question of the speciﬁcity of these 88
genes to CFS/ME, by testing drug-free patients with endogenous
depression. The fact that only ﬁve of these genes were
Table 3 Continued
Gene
symbol
Genbank
accession
CFS/ME subtype
A B C D E F G H
PAPOLA NM_032632 0.47 0.52 0.29 0.79 4.73 0.58 1.25 0.32
PDCD2 NM_002598 3.83 3.44 2.94 5.00 5.74 5.88 5.36 7.37
PDCD6 NM_013232 1.96 2.72 2.53 2.16 4.79 2.69 2.85 2.16
PEX16 NM_004813 2.10 16.10 2.04 8.88 5.92 0.00 2.90 2.80
PGM2 NM_018290 3.23 3.62 2.16 5.99 5.72 4.89 6.13 3.36
PIK3R1 NM_181523 2.06 4.55 0.58 7.17 7.31 0.95 5.48 0.82
PKN1 NM_213560 2.25 3.76 1.27 6.67 6.09 2.39 8.14 2.84
POLR2G NM_002696 1.09 5.58 2.06 1.91 6.01 2.60 3.82 2.91
PPP2R5C NM_002719 2.78 2.62 1.28 9.50 6.14 1.63 7.87 0.84
PRKAA1 NM_006251 2.14 4.10 3.42 3.53 4.17 6.87 7.13 3.11
PRKAR1A NM_002734 2.05 1.85 2.56 4.14 3.66 2.41 6.35 5.41
PUM2 NM_015317 2.81 1.69 0.87 2.85 5.04 1.49 3.84 2.22
RAP2C NM_021183 2.69 2.56 4.75 5.35 25.28 10.61 1.95
REPIN1 NM_013400 2.37 3.85 3.12 1.92 6.62 8.53 7.06 6.52
RNF141 NM_16422 3.64 0.64 2.10 9.85 11.45 6.08 10.83 2.09
SELENBP1 NM_003944 7.88 9.51 3.46 22.18 7.54 2.84 7.65 5.70
SFXN1 NM_022754 1.37 3.46 1.58 1.35 1.40 1.67 1.99 1.72
SHPRH NM_173082 0.82 1.07 0.21 7.17 0.00 0.64
SNAP23 NM_003825 3.46 0.45 1.89 12.62 13.33 4.15 10.19 1.43
SORL1 NM_003105 1.40 1.91 1.60 2.01 1.52 2.47
SOS1 NM_005633 0.70 0.81 1.69 1.09 0.29 1.61 0.90
TAF11 NM_005643 0.56 1.35 1.05 2.13 0.00 0.21 1.23
TCF3 NM_003200 2.00 0.94 1.08 2.83 3.96 3.54 2.52 2.65
TDP1 NM_018319 1.60 5.50 1.38 4.80 11.55 0.96 4.24
TNFRSF1A NM_001065 11.96 4.07 1.36 18.01 13.25 3.30 17.81 2.06
UBTF NM_014233 2.88 3.59 1.82 6.03 6.46 4.81 10.91 6.44
USP38 NM_032557 2.66 0.71 7.40 4.27 7.18 2.94 1.02
WAPAL NM_015045 2.97 5.13 3.63 2.78 1.24 6.04 2.97
WDR26 NM_025160 0.84 0.09 0.63 2.18 1.53 0.80 2.74 1.23
Figure 1 Absolute fold-difference values (mean relative quantity (RQ) in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)/
mean RQ in normal controls) for each of 88 CFS/ME-associated genes in eight CFS/ME subtypes (AeH).
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abnormally expressed in these patients, as compared with
normal controls, supports the view that CFS/ME and endogenous
depression are biologically distinct, and that the psychological
features of CFS/ME are in fact secondary to the pathogenesis.
It is particularly interesting that ﬁve of six CFS/ME patients
with Q-CFS/ME clustered in the same subtype (subtype A). As
these patients had had CFS/ME for several years, this ﬁnding
suggests that they have a common underlying theme, which
may be stable for a long time after the onset of disease. In view
of this, and as various genes within this human gene signature
are closely linked with EBV infection (NFKB1, EGR1, ETS1,
GABPA, CREBBP, CXCR4, EBI2, HIF1A, JAK1, IL6R, IL7R,
PIK3R1) and enterovirus infection (EIF4G1), we tested the serum
samples for markers for four treatable microbial infections that
are well recognised to trigger CFS/ME (EBV, enterovirus, parvo-
virus B19 and C burnetii (the agent of Q fever)) with the
hypothesis that these genomic CFS/ME subtypes may represent
host responses to particular infectious agents.
One patient with subtype E had acute parvovirus B19 at the time
of sampling. This patient’s symptoms were typical of CFS/ME, but
this is not unexpected as parvovirus B19 is a recognised trigger for
CFS/ME.13 The importance of testing for these infections is illustrated
here, as we have shown previously that B19-CFS/ME is highly
responsive to treatment with intravenous immunoglobulin.14
Six patients had acute enterovirus infections (of undetermined
serotype) at the time of sampling, but there was no subtype
relationship, as two patients were found to have each of
subtypes A, E and G. Enteroviruses have long been recognised to
trigger CFS/ME,15 and they have been detected in the stool16 and
stomach epithelium17 in CFS/ME patients. Detection in the
stomach has been shown to be associated with gastrointestinal
symptoms in CFS/ME patients.17 However, in the present study,
patients of subtypes A, E and G did not show gastrointestinal
symptoms more often than the other patients.
Twelve CFS/ME patients and one normal subject had IgG to
C burnetii phase II antigen, suggesting possible acute infection. Five
of these CFS/ME patients were among those with Q-CFS/ME.
The patients in whom these antibodies were detected had
subtypes A, B, D, E and G. Therefore, apart from the patients with
Q-CFS/ME (whose CFS/ME disease onset was associated with
laboratory-documented acute Q fever), there were no subtype-
speciﬁc relationships with C burnetii antibodies.
Figure 2 (a) Medical Outcomes Survey Short Form-36 (SF36) domain and total scores for each chronic fatigue syndrome/myalgic encephalomyelitis
(CFS/ME) subtype: physical function, physical role (RP), bodily pain (BP), general health (GH), vitality (VIT), social functioning (SF), emotional role
(RE), mental health (MH) and total score (Total). (b) Scores indicating occurrence and severity of 11 clinical symptoms for each CFS/ME subtype:
headache (HA), sore throat (ST), swollen glands (GLA), cognitive defect (COG), muscle pain (MP), joint pain (JP), muscle weakness (MW),
post-exertional malaise (PEM), sleep problems (SLE), fainting/dizziness (F/D), gastrointestinal complaints (GI), numbness/tingling (N/T), spatial span
(SSP), verbal recognition memory (VRM). (c) Histogram showing the numbers of CFS/ME patients of each subtype occurring in each of the six
geographical locations. (d) EpsteineBarr virus (EBV) antibody titres (viral capsid antigen (VCA) IgM, VCA IgG, early antigen (EA) IgG, EpsteineBarr
nuclear antigen (EBNA) IgG) in each CFS/ME subtype and the normal comparison group. (e) Distribution of categories of EBV serostatus
(seronegative, primary/re-activation, late phase of infection) in the CFS/ME subtypes, AeH, in CFS/ME (all subtypes combined) and in normal
controls. (f) Log (base 2) of fold-difference values of 10 human genes known to be important in EBV infection, in eight CFS subtypes (AeH).
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The subtype associations with EBV and EBV-linked genes are
interesting, suggesting differences in the role of EBV and conse-
quent host responses in the different subtypes. The ﬁnding of
a noticeably large proportion of CFS/ME patients who were EBV
seronegative (10%), compared with 4% in the normal group, was
quite surprising given the strong link between EBVand CFS/ME.
The fact that ﬁve of these 11 seronegative cases were subtype E is
interesting, but remains unexplained at present.
It has been recognised for some time that subtypes of CFS/ME
exist, and it has been thought that these subtypes may, at least
in part, reﬂect particular aetiological factors.18 A symptom-based
approach has had some success in identifying musculoskeletal,
inﬂammatory and neurological subtypes19; however, these
groups had only minor differences in overall functional severity
in contrast with those of the present study.
It is intriguing that it is possible to identify CFS/ME subtypes
on the basis of expression values for these 88 genes, and even
more so that these subtypes have distinct clinical phenotypes,
with marked differences in the occurrence of particular symp-
toms and their severity. However, what precise sequence of
events is involved in the genesis of the gene signatures in each
subtype remains to be elucidated. Further work is required to
validate and develop these ﬁndings.
Acknowledgements This work was supported by grants from the Chronic Fatigue
Syndrome Research Foundation (CFSRF), UK (salaries of JG and DC), Sir Joseph
Hotung (salary of JRK), and a Wellcome Trust Vacation Scholarship (awarded to LZ).
We thank Dr Frank Boulton, Ms Julie Williams, Mr Peter Rogers, Ms Diana Carr and
the NBS teams of East Dorset for their help in enrolment and sampling of normal
blood donors, Beverley Burke, Deepika Devanur, Joanne Hunt and Robert Petty for
help with sample processing and omission of non-concordant Q-PCR data for
previously published data, and all the patients with CFS/ME and blood donors for their
participation.
Funding Wellcome Trust; CFS Research Foundation.
Competing interests None.
Ethics approval This study was conducted with the approval of the Wandsworth
Research Ethics Committee, St George’s Hospital.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive
approach to its definition and study. International Chronic Fatigue Syndrome Study
Group. Ann Intern Med 1994;121:953e9.
2. A report of the CFS/ME Working Group. Department of Health January 2002.
http://www.dh.gov.uk.
3. Papanicolaou DA, Amsterdam JD, Levine S, et al. Neuroendocrine aspects of
chronic fatigue syndrome. Neuroimmunomodulation 2004;11:65e74.
4. Komaroff AL, Buchwald D. Chronic fatigue syndrome: an update. Annu Rev Med
1998;49:1e13.
5. Devanur LD, Kerr JR. Chronic fatigue syndrome. J Clin Virol 2006;37:139e50.
6. Kaushik N, Fear D, Richards SC, et al. Gene expression in peripheral blood
mononuclear cells from patients with chronic fatigue syndrome. J Clin Pathol
2005;58:826e32.
7. Kerr JR, Petty R, Burke B, et al. Differentially expressed genes in chronic fatigue
syndrome/myalgic encephalomyelitis (CFS/ME) patients reveal seven subtypes with
distinct clinical phenotypes. J Infect Dis 2008;197:1171e84.
8. Kerr JR, Burke B, Petty R, et al. Seven genomic subtypes of chronic fatigue
syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical
phenotypes. J Clin Pathol 2008;61:730e9.
9. Reeves WC, Lloyd A, Vernon SD, et al. Identification of ambiguities in the 1994
chronic fatigue syndrome research case definition and recommendations for
resolution. BMC Health Serv Res 2003;3:25.
10. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale.
J Psychosom Res 1993;37:147e53.
11. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data.
Bioinformatics 2002;18:207e8.
12. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-
wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863e8.
13. Kerr JR, Bracewell J, Laing I, et al. Chronic fatigue syndrome (CFS) and arthralgia
following parvovirus B19 infection. J Rheumatol 2002;29:595e602.
14. Kerr JR, Cunniffe VS, Kelleher P, et al. Successful intravenous immunoglobulin
therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. Clin Infect
Dis 2003;36:e100e6.
15. Kerr JR. Enterovirus infection of the stomach in chronic fatigue syndrome/myalgic
encephalomyelitis. J Clin Pathol 2008;61:1e2.
16. Yousef GE, Bell EJ, Mann GF, et al. Chronic enterovirus infection in patients with
postviral fatigue syndrome. Lancet 1988;1:146e50.
17. Chia JK, Chia AY. Chronic fatigue syndrome is associated with chronic enterovirus
infection of the stomach. J Clin Pathol 2008;61:43e8.
18. Jason LA, Corradi K, Torres-Harding S, et al. Chronic fatigue syndrome: the need for
subtypes. Neuropsychol Rev 2005;15:29e58.
19. Janal MN, Ciccone DS, Natelson BH. Sub-typing CFS patients on the basis of ‘minor’
symptoms. Biol Psychol 2006;73:124e31.
Take-home messages
< Expression of 88 human genes was confirmed as being
significantly different between patients with chronic fatigue
syndrome/myalgic encephalomyelitis (CFS/ME) and normal
controls.
< Gene expression in patients with endogenous depression was
similar to that in normal controls.
< CFS/ME patients can be grouped into genomic subtypes which
have different clinical phenotypes.
< There was evidence of subtype-specific relationships for
EpsteineBarr virus and enterovirus, the two most common
triggers for CFS/ME.
164 J Clin Pathol 2010;63:156e164. doi:10.1136/jcp.2009.072561
Original article
